GLORI™

The world’s first glycoproteomic, liquid-biopsy laboratory-developed test (LDT).

GLORI™ is an LDT for ovarian cancer diagnosis that has been validated using both retrospective patient samples and samples collected prospectively in InterVenn’s VOCAL clinical trial.

Development of GLORI™ was advanced after compelling positive results were obtained in an interim analysis of the VOCAL trial. With an overall accuracy of 86%, GLORI™ performs well among currently available blood-based tests used to manage patients with suspected ovarian cancer. [1,2] The VOCAL clinical trial reached full enrollment of the targeted patient cohort in southeast Asia earlier this year, with the completion of the trial's additional recruitment of patients in the United States and Australia anticipated by the end of the year.

Coming Soon

DAWN™ - InterVenn’s Immuno-Oncology “IO” Test

InterVenn is bringing DAWN™ to the clinic with the goal of helping physicians make the best possible decisions when treating cancer patients with immuno-oncology therapies.

While these IO therapeutics are very effective in some patients (the responders), many patients do not derive benefit (non-responders), are at risk for serious side effects from these costly therapies, and may miss opportunities for alternative therapy options. [3 ,4]

Therefore, there is a strong unmet medical need for tests that can guide selection of the appropriate treatment. We are working closely with members of our world-renowned scientific advisory board to further maximize the clinical benefits of this test.

Other Pipeline Products

Our goal has always been to help patients and physicians by providing products that provide unprecedented insight and benefit. We will continue to advance this cause by introducing new tests and applications and leveraging our analytical platform.

Product Pipeline

Indication	Clinical Application	Phase
Indication	Clinical Application	Proof of Concept	Classifier Validation	LDT Validation	Commercially Available
Glori™	Pelvic Mass Triaging
Dawn™	Immuno-Therapy Response Prediction in MM, NSCLC, and Other Malignancies
Advanced Adenoma	Pre-malignant Detection, Cancer Prevention
Colorectal Cancer	Early Cancer Detection, Colonoscopy Triaging
Prostate Cancer	Differentiation Between Indolent and Aggressive Variants
Non-Alcoholic SteatoHepatitis (NASH)	Early Detection, and Clinical Decision
Hepatocellular Carcinoma (HCC)	Early Detection, and Clinical Decision
Nasopharyngeal Carcinoma	Early Detection, and Clinical Decision
Renal Cell Carcinoma	Differentiation Between Indolent and Aggresive Variants
Pancreas Carcinoma	Early Detection
Non Small Cell Lung Carcinoma (NSCLC)	Early Detection

References

G Xu, D Serie, M Wong, L Shen, P Buckley, P Ramachandran, R Rice, C Lebrilla, K Lindpaintner, H Xu; Targeted Serum Glycoprotein Profiling and Quantification by LC-MS/MS for Detection of Ovarian Cancer. Citation ID 304716, 2020 Jun 4th, Proceedings of the 68th ASMS Conference on Mass Spectrometry and Allied Topics Online Meeting, June 1-12, 2020. https://www.abstracts.asms.org/pages/dashboard.html#/conference/291/toc/291/details
R E Bristow, A Smith, Z Zhang, D W Chan, G Crutcher, E T Fung, D G Munroe; Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic Oncology. 2013 Feb;128(2):252-9. doi: 10.1016/j.ygyno.2012.11.022
G Xu, R Rice, H Huang, K Lindpaintner, JM Prendergast, K Normington, D Frederick, GM Boland, D Serie. Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 387. https://www.abstracts.asms.org/pages/dashboard.html#/conference/291/toc/291/details
Data on file. Pending acceptance of publications for NSCLC and malignant melanoma.